Which has preferable earnings and valuation, IMNM or PHAR?

Pharming Group has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunome $6.94M 444.50 -$212.39M -$2.53 N/A Pharming Group $376.13M 2.16 $2.85M $0.12 95.50

Does the media refer more to IMNM or PHAR?

In the previous week, Immunome had 4 more articles in the media than Pharming Group. MarketBeat recorded 5 mentions for Immunome and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.55 beat Immunome's score of 1.41 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to PHAR or NAMS?

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Pharming Group. MarketBeat recorded 2 mentions for NewAmsterdam Pharma and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.55 beat NewAmsterdam Pharma's score of 0.00 indicating that Pharming Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive NewAmsterdam Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PHAR or CLDX?

In the previous week, Celldex Therapeutics had 2 more articles in the media than Pharming Group. MarketBeat recorded 3 mentions for Celldex Therapeutics and 1 mentions for Pharming Group. Celldex Therapeutics' average media sentiment score of 1.70 beat Pharming Group's score of 1.55 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Celldex Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer BEAM or PHAR?

In the previous week, Beam Therapeutics had 9 more articles in the media than Pharming Group. MarketBeat recorded 10 mentions for Beam Therapeutics and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.55 beat Beam Therapeutics' score of 1.06 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, ALMS or PHAR?

Pharming Group has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $24.05M 61.14 -$243.32M -$3.86 N/A Pharming Group $376.13M 2.16 $2.85M $0.12 95.50

Is ALMS or PHAR more profitable?

Pharming Group has a net margin of 2.51% compared to Alumis' net margin of -5,933.46%. Pharming Group's return on equity of 3.40% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -5,933.46% -93.15% -74.50% Pharming Group 2.51% 3.40% 1.90%

Does the media prefer ALMS or PHAR?

In the previous week, Alumis had 31 more articles in the media than Pharming Group. MarketBeat recorded 32 mentions for Alumis and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.55 beat Alumis' score of 0.42 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 9 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Neutral Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Pharming Group (PHAR) Competitors

$11.46 +0.26 (+2.32%)

As of 09/3/2026 04:00 PM Eastern

Compare

PHAR vs. IMNM, NAMS, CLDX, BEAM, and ALMS

Should you buy Pharming Group stock or one of its competitors? Pharming Group's main competitors and comparable companies include Immunome (IMNM), NewAmsterdam Pharma (NAMS), Celldex Therapeutics (CLDX), Beam Therapeutics (BEAM), and Alumis (ALMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pharming Group compare to Immunome?

Immunome (NASDAQ:IMNM) and Pharming Group (NASDAQ:PHAR) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Immunome presently has a consensus target price of $34.64, suggesting a potential upside of 27.53%. Pharming Group has a consensus target price of $38.67, suggesting a potential upside of 237.41%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Pharming Group has a net margin of 2.51% compared to Immunome's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Pharming Group	2.51%	3.40%	1.90%

44.6% of Immunome shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 7.2% of Immunome shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Immunome had 4 more articles in the media than Pharming Group. MarketBeat recorded 5 mentions for Immunome and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.55 beat Immunome's score of 1.41 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pharming Group has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	444.50	-$212.39M	-$2.53	N/A
Pharming Group	$376.13M	2.16	$2.85M	$0.12	95.50

Immunome has a beta of 2.13, indicating that its stock price is 113% more volatile than the broader market. Comparatively, Pharming Group has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

Summary

Pharming Group beats Immunome on 9 of the 16 factors compared between the two stocks.

How does Pharming Group compare to NewAmsterdam Pharma?

Pharming Group (NASDAQ:PHAR) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Pharming Group has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.16	$2.85M	$0.12	95.50
NewAmsterdam Pharma	$22.50M	137.34	-$203.82M	-$2.16	N/A

Pharming Group currently has a consensus target price of $38.67, suggesting a potential upside of 237.41%. NewAmsterdam Pharma has a consensus target price of $49.73, suggesting a potential upside of 92.37%. Given Pharming Group's higher possible upside, equities research analysts plainly believe Pharming Group is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pharming Group has a net margin of 2.51% compared to NewAmsterdam Pharma's net margin of -3,644.21%. Pharming Group's return on equity of 3.40% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Pharming Group. MarketBeat recorded 2 mentions for NewAmsterdam Pharma and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.55 beat NewAmsterdam Pharma's score of 0.00 indicating that Pharming Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
NewAmsterdam Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pharming Group has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

Summary

Pharming Group beats NewAmsterdam Pharma on 9 of the 17 factors compared between the two stocks.

How does Pharming Group compare to Celldex Therapeutics?

Pharming Group (NASDAQ:PHAR) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Pharming Group currently has a consensus target price of $38.67, indicating a potential upside of 237.41%. Celldex Therapeutics has a consensus target price of $56.08, indicating a potential upside of 42.45%. Given Pharming Group's higher probable upside, equities analysts plainly believe Pharming Group is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, Celldex Therapeutics had 2 more articles in the media than Pharming Group. MarketBeat recorded 3 mentions for Celldex Therapeutics and 1 mentions for Pharming Group. Celldex Therapeutics' average media sentiment score of 1.70 beat Pharming Group's score of 1.55 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Celldex Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pharming Group has a net margin of 2.51% compared to Celldex Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 3.40% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Pharming Group has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

0.0% of Pharming Group shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pharming Group has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.16	$2.85M	$0.12	95.50
Celldex Therapeutics	$1.54M	2,007.61	-$258.76M	-$4.35	N/A

Summary

Pharming Group beats Celldex Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Pharming Group compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Pharming Group (NASDAQ:PHAR) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, Beam Therapeutics had 9 more articles in the media than Pharming Group. MarketBeat recorded 10 mentions for Beam Therapeutics and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.55 beat Beam Therapeutics' score of 1.06 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Beam Therapeutics currently has a consensus price target of $49.00, indicating a potential upside of 66.33%. Pharming Group has a consensus price target of $38.67, indicating a potential upside of 237.41%. Given Pharming Group's higher possible upside, analysts plainly believe Pharming Group is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Pharming Group has a net margin of 2.51% compared to Beam Therapeutics' net margin of -54.75%. Pharming Group's return on equity of 3.40% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Pharming Group	2.51%	3.40%	1.90%

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Beam Therapeutics has a beta of 2.22, suggesting that its stock price is 122% more volatile than the broader market. Comparatively, Pharming Group has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

Pharming Group has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.78	-$79.99M	-$0.86	N/A
Pharming Group	$376.13M	2.16	$2.85M	$0.12	95.50

Summary

Pharming Group beats Beam Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Pharming Group compare to Alumis?

Alumis (NASDAQ:ALMS) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Pharming Group has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	61.14	-$243.32M	-$3.86	N/A
Pharming Group	$376.13M	2.16	$2.85M	$0.12	95.50

Alumis presently has a consensus target price of $33.27, indicating a potential upside of 192.89%. Pharming Group has a consensus target price of $38.67, indicating a potential upside of 237.41%. Given Pharming Group's higher probable upside, analysts clearly believe Pharming Group is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Alumis has a beta of -0.81, meaning that its share price is 181% less volatile than the broader market. Comparatively, Pharming Group has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

0.0% of Pharming Group shares are held by institutional investors. 33.7% of Alumis shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Alumis had 31 more articles in the media than Pharming Group. MarketBeat recorded 32 mentions for Alumis and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.55 beat Alumis' score of 0.42 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	9 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pharming Group has a net margin of 2.51% compared to Alumis' net margin of -5,933.46%. Pharming Group's return on equity of 3.40% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-93.15%	-74.50%
Pharming Group	2.51%	3.40%	1.90%

Summary

Pharming Group beats Alumis on 11 of the 17 factors compared between the two stocks.

Get Pharming Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAR vs. The Competition

Export

Metric	Pharming Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$792.72M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	95.50	12.66	273.29	25.38
Price / Sales	2.16	1,309.08	613.45	92.55
Price / Cash	55.85	106.87	77.82	52.26
Price / Book	3.00	16.29	12.89	6.14
Net Income	$2.85M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-2.05%	0.34%	0.60%	-0.27%
1 Month Performance	11.70%	8.52%	5.73%	0.68%
1 Year Performance	-22.93%	52.66%	25.35%	14.84%

Pharming Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAR Pharming Group	3.7839 of 5 stars	$11.46 +2.3%	$38.67 +237.4%	-20.2%	$792.72M	$376.13M	95.50	280	Positive News
IMNM Immunome	3.0452 of 5 stars	$29.69 +6.0%	$34.64 +16.7%	+165.0%	$3.37B	$6.94M	N/A	40	Positive News
NAMS NewAmsterdam Pharma	2.1772 of 5 stars	$27.66 +3.0%	$49.73 +79.8%	+3.9%	$3.30B	$7.12M	N/A	4
CLDX Celldex Therapeutics	2.7971 of 5 stars	$41.19 +1.5%	$56.08 +36.2%	+66.8%	$3.23B	$1.54M	N/A	150	Positive News
BEAM Beam Therapeutics	2.258 of 5 stars	$30.93 +9.2%	$49.00 +58.4%	+57.0%	$3.20B	$139.74M	N/A	510	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAR) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharming Group (PHAR) Competitors

PHAR vs. IMNM, NAMS, CLDX, BEAM, and ALMS

How does Pharming Group compare to Immunome?

Summary

How does Pharming Group compare to NewAmsterdam Pharma?

Summary

How does Pharming Group compare to Celldex Therapeutics?

Summary

How does Pharming Group compare to Beam Therapeutics?

Summary

How does Pharming Group compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pharming Group (PHAR) Competitors

PHAR vs. IMNM, NAMS, CLDX, BEAM, and ALMS

How does Pharming Group compare to Immunome?

Do analysts prefer IMNM or PHAR?

Is IMNM or PHAR more profitable?

Do institutionals & insiders hold more shares of IMNM or PHAR?

Does the media refer more to IMNM or PHAR?

Which has preferable earnings and valuation, IMNM or PHAR?

Which has more risk and volatility, IMNM or PHAR?

Summary

How does Pharming Group compare to NewAmsterdam Pharma?

Which has higher earnings & valuation, PHAR or NAMS?

Do analysts recommend PHAR or NAMS?

Do insiders and institutionals hold more shares of PHAR or NAMS?

Is PHAR or NAMS more profitable?

Does the media refer more to PHAR or NAMS?

Which has more risk and volatility, PHAR or NAMS?

Summary

How does Pharming Group compare to Celldex Therapeutics?

Do analysts prefer PHAR or CLDX?

Does the media refer more to PHAR or CLDX?

Is PHAR or CLDX more profitable?

Which has more risk and volatility, PHAR or CLDX?

Do institutionals & insiders believe in PHAR or CLDX?

Which has higher valuation and earnings, PHAR or CLDX?

Summary

How does Pharming Group compare to Beam Therapeutics?

Does the media prefer BEAM or PHAR?

Do analysts rate BEAM or PHAR?

Is BEAM or PHAR more profitable?

Do institutionals & insiders believe in BEAM or PHAR?

Which has more risk & volatility, BEAM or PHAR?

Which has stronger valuation & earnings, BEAM or PHAR?

Summary

How does Pharming Group compare to Alumis?

Which has better valuation & earnings, ALMS or PHAR?

Do analysts prefer ALMS or PHAR?

Which has more volatility & risk, ALMS or PHAR?

Do institutionals & insiders believe in ALMS or PHAR?

Does the media prefer ALMS or PHAR?

Is ALMS or PHAR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools